Role of the Renin Angiotensin Aldosterone System in the Mechanisms of Transition to Heart Failure in Abdominal Obesity

Role of the Renin Angiotensin Aldosterone System and Remodeling of the Matrix Cardiac Extra Cellular in the Mechanisms of Transition to Heart Failure in Abdominal Obesity: Prospective Longitudinal Study R2C2 II

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01716819

Acronym

R2C2-II

Enrollment

101

Registered

2012-10-30

Start date

2012-11-30

Completion date

2015-03-31

Last updated

2015-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity, Abdominal

Keywords

Heart failure, abdominal obesity, RAAS

Brief summary

R2C2 study has shown that abdominal obesity is associated with a cardiac and vascular remodelling in healthy volunteers. This remodelling is correlated with renin-angiotensin aldosterone system (RAAS) activation and/or systemic fibrosis. R2C2 II study is designed to confirm the hypothesis that RAAS is associated with an early remodelling and implicated in the transition to cardiac failure in abdominal obesity.

Detailed description

Follow up of abdominal obesity patients from the R2C2 cohort study.

Interventions

OTHERUrine sample

dosages on one spot and 24h collection

OTHERBlood sample

dosages

OTHERAssessment of sleep apnea syndrome

OTHERElectrocardiogram

OTHERGlucose tolerance test

OTHEREchocardiography

OTHERcardiac and abdominal magnetic resonance imaging

OTHERAmbulatory blood pressure monitoring

OTHEREchotracking

OTHERPulse wave velocity

OTHERComposition of body mass by Dual x-ray absorptiometry

Study design

Allocation

Intervention model

SINGLE_GROUP

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

43 Years to 72 Years

Healthy volunteers

Yes

Inclusion criteria

* Being a former member of R2C2 study, abdominal obese group. * Having signed the informed consent (refusing to participate to the genetic study is not an

Exclusion criteria

). * being affiliated to health insurance scheme. Inclusion Criteria of R2C2 study: * Men and women aged between 40 and 65 year's old * Caucasian * Born or living in France for at least 10 years * Presenting an abdominal obesity defined by a waist circumference \>94 cm in men and ≥ 80 cm in women, associated or not with untreated hypertension or hypertension treated for less than one year * Having signed the informed consent

Design outcomes

Primary

Measure	Time frame	Description
cardiac extracellular matrix remodelling	3-7 years	Initial values of cardiac extracellular matrix remodelling biomarkers and the evolution of biomarkers at 3-7 years

Secondary

Measure	Time frame	Description
Cardiac and arterial phenotype	3-7 years	Evolution of cardiac and vascular phenotype in 3-7 years.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026